Home › Biliary Tract Cancer
Biliary Tract Cancer clinical trials recruiting in the U.S.
41 studies for Biliary Tract Cancer are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX19 studies
- Los Angeles, CA12 studies
- New York City, NY11 studies
- Nashville, TN11 studies
- Boston, MA11 studies
- Arlington, VA9 studies
- Baltimore, MD9 studies
- Dallas, TX8 studies
- Baldwin Park, CA7 studies
- San Antonio, TX7 studies
- Columbus, OH6 studies
- Washington, DC6 studies
- Madison, WI6 studies
- Philadelphia, PA6 studies
- Pittsburgh, PA6 studies
- Detroit, MI5 studies
- Seattle, WA5 studies
- Cleveland, OH5 studies
- Louisville, KY5 studies
- Miami, FL5 studies
- Grand Rapids, MI5 studies
- Tampa, FL4 studies
- Orange, CA4 studies
- Providence, RI4 studies
- Queens, NY4 studies
- Aurora, CO4 studies
- St. Louis, MO4 studies
- Denver, CO4 studies
- Chicago, IL4 studies
- Orlando, FL4 studies
- Edison, NJ3 studies
- Santa Monica, CA3 studies
- Salt Lake City, UT3 studies
- Birmingham, AL3 studies
- Portland, OR3 studies
- Tucson, AZ3 studies
- San Diego, CA3 studies
- San Francisco, CA3 studies
- Sarasota, FL3 studies
By state
- Alabama3 studies
- Arizona4 studies
- California21 studies
- Colorado8 studies
- Connecticut3 studies
- District of Columbia3 studies
- Florida15 studies
- Georgia4 studies
- Illinois6 studies
- Kentucky5 studies
- Maryland12 studies
- Massachusetts11 studies
- Michigan11 studies
- Minnesota5 studies
- Missouri5 studies
- New Jersey4 studies
- New York15 studies
- North Carolina4 studies
- Ohio9 studies
- Oregon3 studies
- Pennsylvania10 studies
- Rhode Island4 studies
- Tennessee12 studies
- Texas26 studies
- Utah4 studies
- Virginia10 studies
- Washington6 studies
- Wisconsin6 studies
Recently updated studies
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
RecruitingObservational study
Ages 2 to 100 · All sexes · Updated Nov 12, 2026 · NCT01950572Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Recruiting
Ages 18 to 99 · All sexes · Updated Nov 12, 2026 · NCT04907643A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
RecruitingPhase 1
Ages 16 and older · All sexes · Updated Nov 12, 2026 · NCT07197554A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07458347A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07020221D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06622057A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06760819CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07909031A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Oct 30, 2026 · NCT05849480A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06428409Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06282575A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06330064AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Oct 16, 2026 · NCT07038343A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT07807956Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT06239194Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT06084481Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Oct 13, 2026 · NCT06467357Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06293898AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06219941A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07265674Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05482893A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07221253Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT05523947Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
RecruitingPhase 2
Ages 18 to 130 · All sexes · Updated Sep 23, 2026 · NCT05489211SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT07812805From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.